George H. Talbot

Best Publications

• Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

  Helen W. Boucher;George H. Talbot;John S. Bradley;John S. Bradley;John E. Edwards;John E. Edwards

  7288
  Citations

• Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

  George H. Talbot;John Bradley;John Bradley;John E. Edwards;David Gilbert

  1541
  Citations

• 10 × '20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

  Helen W. Boucher;George H. Talbot;Daniel K. Benjamin;Daniel K. Benjamin;John Bradley;John Bradley

  876
  Citations

• Once-weekly dalbavancin versus daily conventional therapy for skin infection.

  Helen W Boucher;Mark Wilcox;George H Talbot;Sailaja Puttagunta

  530
  Citations

• Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

  G. Ralph Corey;Mark Wilcox;George H. Talbot;H. David Friedland

  326
  Citations

• The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

  R. C. Moellering;P. K. Linden;J. Reinhardt;E. A. Blumberg

  297
  Citations

• Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community-Acquired Pneumonia

  Thomas M. File;Thomas M. File;Donald E. Low;Donald E. Low;Paul B. Eckburg;George H. Talbot

  252
  Citations

• CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

  Mark H. Wilcox;G. Ralph Corey;George H. Talbot;Dirk Thye

  219
  Citations

• FOCUS 1: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

  Thomas M. File;Donald E. Low;Paul B. Eckburg;George H. Talbot

  214
  Citations

• FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

  Donald E. Low;Thomas M. File;Paul B. Eckburg;George H. Talbot

  213
  Citations

• Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections

  Unknown

  211
  Citations

• In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

  Yigong Ge;Donald Biek;George H. Talbot;Daniel F. Sahm

  203
  Citations

• Invasive Aspergillus Rhinosinusitis in Patients with Acute Leukemia

  Unknown

  196
  Citations

• Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

  James A McKinnell;Jamie P Dwyer;George H Talbot;Lynn E Connolly

  192
  Citations

• Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia

  Steven M. Albelda;George H. Talbot;Stanton L. Gerson;Wallace T. Miller

  181
  Citations

• CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

  Unknown

  169
  Citations

• Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia.

  S M Albelda;G H Talbot;S L Gerson;W T Miller

  168
  Citations

• Risk factors for amphotericin B-associated nephrotoxicity

  Melanie A. Fisher;George H. Talbot;George H. Talbot;Greg Maislin;Greg Maislin;Bernadette P. McKeon;Bernadette P. McKeon

  164
  Citations

• Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign.

  W. B. Gefter;S. M. Albelda;G. H. Talbot;Stanton L Gerson

  160
  Citations

• The Infectious Diseases Society of America’s 10 × ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × ’20 a Possibility?

  George H Talbot;Amanda Jezek;Barbara E Murray;Ronald N Jones

  136
  Citations